SCA
PCSA icon

Sassicaia Capital Advisers’s Processa Pharmaceuticals PCSA Stock Holding History

Sassicaia Capital Advisers’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-639
Closed -$3.07K – 46
2025
Q3 		$3.07K Buy
+639
New +$3.37K ﹤0.01% 37

Other funds holding PCSA

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Sassicaia Capital Advisers's PCSA Position: Q4 2025 in Review

Sassicaia Capital Advisers sold out of Processa Pharmaceuticals (PCSA) in Q4 2025, closing a stake of 639 shares — an estimated $3.07K sold.

Sassicaia Capital Advisers first reported a position in PCSA in Q3 2025 and held it in 1 quarter. The position peaked at $3.07K in Q3 2025. 10 funds tracked by Wall St. Rank hold PCSA as of Q4 2025.

  • Sassicaia Capital Advisers reported no remaining Processa Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 639 Processa Pharmaceuticals shares in Q4 2025, an estimated $3.07K.
  • Sassicaia Capital Advisers first reported a position in Processa Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Sassicaia Capital Advisers's Processa Pharmaceuticals position peaked at $3.07K in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q4 2025.

Based on Sassicaia Capital Advisers's 13F filing for Q4 2025, filed 13 Feb 2026.